NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

Inclusion Criteria: * Have one of the following clinical diagnoses for at least 3 months prior to screening a) schizophrenia or schizoaffective disorder; b) mood disorder; or c) gastrointestinal disorder (e.g., gastroparesis, gastroesophageal reflux disease) * Have a clinical diagnosis of neuroleptic-induced tardive dyskinesia for at least 3 months prior to screening. * Be receiving a stable dose of antipsychotic medication for a minimum of 30 days before study start. Subjects who are not using antipsychotic medication must have stable psychiatric status. * Have the doses of concurrent medications and the conditions being treated be stable for a minimum of 30 days before study start and be expected to remain stable during the study. * Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal birth control during the study. * Female subjects must not be pregnant. * Be in good general health and expected to complete the clinical study as designed. * Have a body mass index (BMI) of 18 to 38 kg/m2 (both inclusive). * Have a negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and study start, except for any subject receiving a stable dose of benzodiazepine. * Have a negative alcohol breath test at screening and study start. Exclusion Criteria: * Have an active clinically significant unstable medical condition within 1 month (30 days) prior to screening. * Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start(nicotine and caffeine dependence are not exclusionary). * Have a known history of neuroleptic malignant syndrome. * Have a significant risk of suicidal or violent behavior. * Receiving any excluded concomitant medication such as reserpine, metoclopramide, stimulants, or tetrabenazine. * Receiving medication for the treatment of tardive dyskinesia. * Have a positive human immunodeficiency virus antibody, (HIV-Ab), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody result at screening or have a history of positive result. * Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study. * Have an allergy, hypersensitivity, or intolerance to tetrabenazine. * Have had previous exposure with NBI-98854.